The Union health ministry has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, that would require manufacturers of antimicrobials to obtain central permission before applying to a state for a manufacturing licence.

According to a ministry statement issued on Thursday, the draft notification G.S.R. 983(E) dated November 6 proposes to bring antimicrobials within the definition of "new drug" under the rules. Manufacturers would then need approval from the Central Licensing Authority before seeking a manufacturing licence from the concerned state licensing authority. The ministry said the move is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products.

At present, state licensing authorities grant manufacturing licences for these products. The amendment follows concerns that some products were cleared without adequate regulatory scrutiny, including studies such as bioavailability/bioequivalence and stability studies, according to persons aware of the matter. The ministry said substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety.

A senior health ministry official, speaking on condition of anonymity, said the change will apply prospectively. Licences already granted will remain valid and existing holders will not have to reapply. The official described the proposal as an additional regulatory safeguard against antimicrobial resistance, part of the government's broader efforts to promote responsible use of antimicrobials and protect patient safety. The draft has been issued to invite objections and suggestions from stakeholders and the public within 30 days before the central government considers it for finalisation.